title: Antihyperuricemic effect of liquiritigenin in potassium oxonate-induced hyperuricemic rats.
abstract: The aim is to investigate the anti-hyperuricemic and renal protective effects of liquiritigenin in potassium oxonate-induced hyperuricemic rats. Hyperuricemia in rats was induced were induced with potassium oxonate (250mg/kg) intragastrically for 7 days, and liquiritigenin (20, 40mg/kg) and allopurinol (5mg/kg) were daily administrated to the rats orally 1h after the potassium oxonate exposure. Liquiritigenin significantly reversed the elevated productions of uric acid in serum and urine and pro-inflammation cytokines in serum and kidney, which shown that liquiritigenin has renal protective effects. Histological study shows that liquiritigenin inhibited severe necrosis and inflammatory cell infiltration in potassium oxonate-treated rats. Furthermore, liquiritigenin mediated the activities of aquaporins 4 (AQP4), and regulated the activation of NF-κB p65 and the degradation of IκBα. Finally, significant increases of nod-like receptor protein 3 (NLRP3) inflammasome, apoptosis-associated speck-like protein adaptor (ASC) adaptor and cleaved caspased-1 were restored by liquiritigenin. Therefore, liquiritigenin might improve renal inflammation by suppressing renal AQP4/NF-κB/IκBα and NLRP3 inflammasome activation in hyperuricemic rats.
authors.affiliation: Central Laboratory, Nanjing Municipal Hospital of T.C.M, The Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing 210001, China.
authors.forename: Long
authors.initials: L
authors.lastname: Hongyan
authors.affiliation: Department of Rheumatology, Nanjing Municipal Hospital of T.C.M, The Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing 210001, China. Electronic address: wusulingtcm@163.com.
authors.forename: Wu
authors.initials: W
authors.lastname: Suling
authors.affiliation: Central Laboratory, Nanjing Municipal Hospital of T.C.M, The Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing 210001, China.
authors.forename: Zhu
authors.initials: Z
authors.lastname: Weina
authors.affiliation: Central Laboratory, Nanjing Municipal Hospital of T.C.M, The Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing 210001, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yajie
authors.affiliation: Central Laboratory, Nanjing Municipal Hospital of T.C.M, The Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing 210001, China.
authors.forename: Ruan
authors.initials: R
authors.lastname: Jie
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D044950:Flavanones / Q000494:pharmacology / Q000627:therapeutic use*; D006074:Gout Suppressants / Q000494:pharmacology / Q000627:therapeutic use*; D033461:Hyperuricemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D010094:Oxonic Acid / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: D044950:Flavanones; D006074:Gout Suppressants; D014527:Uric Acid; C489337:potassium oxonate; D010094:Oxonic Acid; C083152:liquiritigenin
keywords: AQP4; Hyperuricemia; Inflammation; Liquiritigenin; NLRP3